Figure S1

**Figure S1. Feature selection using** **LASSO model.** (A) LASSO analysis of lactate signature with minimum lambda value. (B) Coefficient of lactate signature in LASSO model.

Figure S2

**Figure S2. Comparison of LaSig among different clinical features.**

Figure S3

**Figure S3. Association analysis of LaSig and PD-1 expression in different cancers.**



**Figure S3. LaSig incorporates clinicopathological features to further improve prognostic models.** (A-B) ROC curve was used to evaluate the predictive efficacy of LaSig in TCGA-LUAD and GSE19188. (C) Nomograms for forecasting the 1 -, 3 -, and 5-year patient survival rate using the TCGA-LUAD dataset.